Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ...

The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ ...

As we await the release of the revised U.S. dietary guidelines, vintner and medical doctor Laura Catena argues recent ...

JMP Securities analyst Silvan Tuerkcan has reiterated their bullish stance on VOR stock, giving a Buy rating on November 8. Silvan ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...

Anna Lindstrand at the research group Rare Diseases receives SEK 1.200.000 for the project "Resolving Structural Variant Complexity in Hematological Malignancies". Ann Nordgren at the research group ...

HC Wainwright reaffirmed their buy rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research note issued to investors on Friday,Benzinga reports. The firm currently has a $17.50 price ...

Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s ...

Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indications ...

The Company will in due course elucidate this new addition to its pipeline in more detail to expand the pipeline beyond hematological cancers and solid tumor oncology. "Clever-1 is a master regulator ...